Given this critical role, androgen deprivation therapies/AR signalling inhibitors (ADTs/ARSis) that target AR function (eg bicalutamide, enzalutamide, darolutamide, and apalutamide) or inhibit androgen production (eg abiraterone) are the mainstay of systemic PCa treatments. This evidence concerns the gene AR and posterior cortical atrophy.